Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

NCT02676596 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia

Interventions

DRUG: K-312 10 mg QD
DRUG: K-312 25 mg QD
DRUG: K-312 50 mg QD
DRUG: K-312 100 mg QD
DRUG: K-312 200 mg QD
DRUG: K-312 400 mg QD
OTHER: Placebo

Sponsor

Kowa Research Institute, Inc.